Trial Information

Summary: Phase III: Multicenter Study to Investigate Safety and Efficacy of Treanda in Patients with Indolent NHL Who are Refractory to Rituximab

Small lymphocytic, lymphoplasmacytic, splenic marginal zone B-cell, extra-nodal zone B-cell, nodal marginal zone and follicle center (grades 1-3) allowed.

Must have one of the following:

  • Refractory after rituxan only: 4 doses 375mg/m2 wkly
  • Refractory after rituxan maintenance: 4 doses 375mg/m2 wkly or in combination with chemo, on a maintenance regimen, progress before next scheduled dose or w/in 6 mos.
  • Refractory after rituxan-chemo combination: 4 doses 375mg/m2 wkly in combination w/chemo if no response or progress w/in 6 mos.
  • Must have 1 prior chemo and maximum of 3. PS 0-2. 28 day washout for radiation, chemo or immunotherapy.

Exclusions:

  • No prior hi-dose chemo w/ allogenic stem cell support.
  • No transformed disease, CNS or leptomeningeal.

Contact:

Cathy Spears, RN, Director, St. Francis Clinical Research
American Health Network of Indiana LLC, Oncology Division
1500 Albany St., Suite 1001
Beech Grove, IN 46107
Telephone: 317-782-7819
Fax: 317-782-7828
Email:

Profile Page: American Health Network of Indiana LLC, Oncology Division, Beech Grove, IN

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:53 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA